Effector Therapeutics Inc (EFTR) — Financial Flexibility Index
Effector Therapeutics Inc (EFTR) has a Financial Flexibility Index of -0.28x as of March 2024. Free cash flow of $-7.28 Million (operating CF $-7.28 Million minus capex $0.00) represents 0% of total liabilities ($26.30 Million). Check Effector Therapeutics Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Effector Therapeutics Inc Financial Flexibility Index (2019–2023)
Historical Financial Flexibility Index trend for Effector Therapeutics Inc across 5 annual periods. For the full cash flow conversion analysis, see EFTR cash generation efficiency.
Annual Financial Flexibility Index for Effector Therapeutics Inc (2019–2023)
Year-by-year free cash flow to debt coverage for Effector Therapeutics Inc. Explore Effector Therapeutics Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2023 | -1.12x | $-29.45 Million | $-29.55 Million | $26.34 Million | ▼ -9.5% |
| 2022 | -1.02x | $-25.71 Million | $-25.90 Million | $25.18 Million | ▼ -51.1% |
| 2021 | -0.68x | $-24.85 Million | $-24.89 Million | $36.77 Million | ▼ -819.4% |
| 2020 | 0.09x | $13.99 Million | $13.84 Million | $148.95 Million | ▲ +106.4% |
| 2019 | -1.46x | $-27.59 Million | $-27.60 Million | $18.93 Million | — |